[go: up one dir, main page]

WO2003008577A1 - Novel transformed cells, method of screening antiaging agent and antiaging agents - Google Patents

Novel transformed cells, method of screening antiaging agent and antiaging agents Download PDF

Info

Publication number
WO2003008577A1
WO2003008577A1 PCT/JP2002/007182 JP0207182W WO03008577A1 WO 2003008577 A1 WO2003008577 A1 WO 2003008577A1 JP 0207182 W JP0207182 W JP 0207182W WO 03008577 A1 WO03008577 A1 WO 03008577A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
antiaging
transformed cells
screening
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007182
Other languages
English (en)
French (fr)
Inventor
Fuyuki Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2454873A priority Critical patent/CA2454873C/en
Priority to JP2003514894A priority patent/JPWO2003008577A1/ja
Priority to EP02746067A priority patent/EP1408109B1/en
Priority to DE60227524T priority patent/DE60227524D1/de
Priority to DK02746067T priority patent/DK1408109T3/da
Priority to US10/484,033 priority patent/US7291499B2/en
Publication of WO2003008577A1 publication Critical patent/WO2003008577A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating And Analyzing Materials By Characteristic Methods (AREA)
PCT/JP2002/007182 2001-07-16 2002-07-15 Novel transformed cells, method of screening antiaging agent and antiaging agents Ceased WO2003008577A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2454873A CA2454873C (en) 2001-07-16 2002-07-15 Novel transformed cell, method for screening anti-aging agent, and anti-aging agent
JP2003514894A JPWO2003008577A1 (ja) 2001-07-16 2002-07-15 新規の形質転換細胞、抗老化剤のスクリーニング方法および抗老化剤
EP02746067A EP1408109B1 (en) 2001-07-16 2002-07-15 Novel method for the induction of cellular senescence and method for screening anti-aging agent
DE60227524T DE60227524D1 (de) 2001-07-16 2002-07-15 Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung
DK02746067T DK1408109T3 (da) 2001-07-16 2002-07-15 Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel
US10/484,033 US7291499B2 (en) 2001-07-16 2002-07-15 Transformed cell, method of screening anti-aging agent and anti-aging agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001215576 2001-07-16
JP2001-215576 2001-07-16
JP2001-286412 2001-09-20
JP2001286412 2001-09-20

Publications (1)

Publication Number Publication Date
WO2003008577A1 true WO2003008577A1 (en) 2003-01-30

Family

ID=26618801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007182 Ceased WO2003008577A1 (en) 2001-07-16 2002-07-15 Novel transformed cells, method of screening antiaging agent and antiaging agents

Country Status (8)

Country Link
US (1) US7291499B2 (ja)
EP (1) EP1408109B1 (ja)
JP (1) JPWO2003008577A1 (ja)
AT (1) ATE400649T1 (ja)
CA (1) CA2454873C (ja)
DE (1) DE60227524D1 (ja)
DK (1) DK1408109T3 (ja)
WO (1) WO2003008577A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045334A (ja) * 2009-08-28 2011-03-10 Kyushu Univ 細胞老化関連因子

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971792B1 (fr) * 2011-02-18 2017-06-23 Isp Investments Inc Methode in vitro pour identifier des agents modulateurs de la senescence cellulaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09271395A (ja) * 1996-04-02 1997-10-21 Nippon Zoki Pharmaceut Co Ltd 内皮細胞を用いたスクリーニング法
WO1998005761A1 (en) * 1996-08-07 1998-02-12 The General Hospital Corporation Age-1 polypeptides and related molecules and methods
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO2000000491A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2255579A1 (en) 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
AU4273099A (en) 1998-06-24 2000-01-10 Medical Research Council Polypeptides, polynucleotides and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09271395A (ja) * 1996-04-02 1997-10-21 Nippon Zoki Pharmaceut Co Ltd 内皮細胞を用いたスクリーニング法
WO1998005761A1 (en) * 1996-08-07 1998-02-12 The General Hospital Corporation Age-1 polypeptides and related molecules and methods
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO2000000491A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MORIGUCHI T. ET AL.: "A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3", J. BIOL. CHEM., vol. 271, no. 23, 1996, pages 13675 - 13679, XP002956181 *
RAINGEAUD J. ET AL.: "MKK3- and MKK6- regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway", MOL. CELL. BIOL., vol. 16, no. 3, 1996, pages 1247 - 1255, XP000673937 *
SUH Y. ET AL.: "Differential activation of mitogen-activated protein kinase by methyl methanesulfonate in the kidney of young and old rats", MUTATION RESEARCH, vol. 497, no. 1/2, 18 October 2001 (2001-10-18), pages 11 - 18, XP002956182 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045334A (ja) * 2009-08-28 2011-03-10 Kyushu Univ 細胞老化関連因子

Also Published As

Publication number Publication date
US20050288216A1 (en) 2005-12-29
EP1408109A1 (en) 2004-04-14
ATE400649T1 (de) 2008-07-15
CA2454873C (en) 2013-10-01
DK1408109T3 (da) 2008-10-06
US7291499B2 (en) 2007-11-06
JPWO2003008577A1 (ja) 2004-11-11
EP1408109A4 (en) 2005-02-16
CA2454873A1 (en) 2003-01-30
DE60227524D1 (de) 2008-08-21
EP1408109B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
WO2004110352A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
AU2002328750A1 (en) Distributed security architecture for storage area networks (san)
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
MXPA03002291A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
MXPA03005610A (es) Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
IL161812A (en) STABLE FORMULATION OF Apo-2 LIGAND AND A METHOD FOR MANUFACTURING IT
WO2004025887A3 (en) Network access points using multiple devices
AU2003225933A1 (en) AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
ZA9811178B (en) Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
WO2001059066A3 (en) Protein design automation for protein libraries
NO20030381D0 (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
WO2005045689A8 (en) Methods and systems for network coordination
ATE376587T1 (de) Granulat mit hoher schlagfestigkeit
WO2004062475A3 (en) Fluorescent assays for protein kinases
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
AU2002236300A1 (en) Novel protein, gene encoding the same and method of using the same
WO2003050260A3 (en) Streptavidin expressed gene fusions and methods of use thereof
ZA200401401B (en) Fungicide active substance combinations.
WO2003042273A8 (en) Compounds containing quaternary carbons, medical devices, and methods
AU2002365211A1 (en) 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
WO2003008577A1 (en) Novel transformed cells, method of screening antiaging agent and antiaging agents
AU2001234208A1 (en) Antagonists for nicotinic acetylcholine receptor, which are containing borneol or camphor as an active ingredient
WO2003034027A3 (en) Whole cell assay
WO2003027242A3 (en) Fas ligand
WO2003027300A3 (en) Use of aminoglycoside resistance gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003514894

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002746067

Country of ref document: EP

Ref document number: 10484033

Country of ref document: US

Ref document number: 2454873

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002746067

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002746067

Country of ref document: EP